These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 38507250

  • 1. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.
    Muller AE, De Winter BCM, Koch BCP.
    J Antimicrob Chemother; 2024 May 02; 79(5):1093-1100. PubMed ID: 38507250
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
    Ambrose PG, Bhavnani SM, Jones RN.
    Antimicrob Agents Chemother; 2003 May 02; 47(5):1643-6. PubMed ID: 12709334
    [Abstract] [Full Text] [Related]

  • 3. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP.
    Antimicrob Agents Chemother; 2012 Jan 02; 56(1):544-9. PubMed ID: 22064538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
    Gill CM, Abdelraouf K, Nicolau DP.
    J Antimicrob Chemother; 2021 Mar 12; 76(4):993-1000. PubMed ID: 33438033
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S, Pai MP, Lodise TP.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2813-2816. PubMed ID: 29091209
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan 01; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 9. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 01; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 10. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O, Elhelali N, Léotard S, Jacolot A, Laurent F, Samii K, Petitjean O, Nordmann P.
    J Antimicrob Chemother; 1999 Jul 01; 44(1):91-7. PubMed ID: 10459815
    [Abstract] [Full Text] [Related]

  • 11. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB.
    Pharmacotherapy; 1999 Dec 01; 19(12):1392-9. PubMed ID: 10600088
    [Abstract] [Full Text] [Related]

  • 12. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.
    Int J Antimicrob Agents; 2013 Jan 01; 41(1):52-6. PubMed ID: 23228881
    [Abstract] [Full Text] [Related]

  • 13. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
    Patel N, Scheetz MH, Drusano GL, Lodise TP.
    Antimicrob Agents Chemother; 2010 Jan 01; 54(1):460-5. PubMed ID: 19858253
    [Abstract] [Full Text] [Related]

  • 14. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov 01; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 15. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H, Tomini E, Emirian A, Join-Lambert O, Lécuyer H, Zahar JR, Jullien V.
    Int J Antimicrob Agents; 2017 Jan 01; 49(1):62-66. PubMed ID: 27876276
    [Abstract] [Full Text] [Related]

  • 16. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.
    Paterson DL, Muto CA, Ndirangu M, Linden PK, Potoski BA, Capitano B, Bonomo RA, Aron DC, Donskey CJ.
    Antimicrob Agents Chemother; 2008 Feb 01; 52(2):465-9. PubMed ID: 18025111
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    Thorsted A, Kristoffersson AN, Maarbjerg SF, Schrøder H, Wang M, Brock B, Nielsen EI, Friberg LE.
    J Antimicrob Chemother; 2019 Oct 01; 74(10):2984-2993. PubMed ID: 31273375
    [Abstract] [Full Text] [Related]

  • 18. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, Crumby AS, Kays MB.
    Antimicrob Agents Chemother; 2016 Jan 01; 60(1):522-31. PubMed ID: 26552978
    [Abstract] [Full Text] [Related]

  • 19. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales.
    Cojutti PG, Pai MP, Tonetti T, Siniscalchi A, Viale P, Pea F.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0140423. PubMed ID: 38411995
    [Abstract] [Full Text] [Related]

  • 20. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK, Grupper M, Nicolau DP, Kuti JL.
    J Pharm Pract; 2017 Dec 03; 30(6):593-599. PubMed ID: 29121839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.